UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Platinum resistance in breast and ovarian cancer cell lines

Journal of experimental & clinical cancer research, 2011-10, Vol.30 (1), p.91-91, Article 91

Eckstein, Niels

2011

Volltextzugriff (PDF)

Key results of a series of surveys among German pharmacies, physicians, patients and stakeholders regarding further triptans as potential OTC products

Journal of public health, 2022-02, Vol.30 (2), p.409-415

2022

Volltextzugriff (PDF)

To switch or not to switch—first Germany-wide study from the perspective of pharmacists in the European environment

Journal of public health, 2021-02, Vol.29 (1), p.9-17

2021

Volltextzugriff (PDF)

Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent

Journal of cancer research and clinical oncology, 2021-03, Vol.147 (3), p.779-792

2021

Volltextzugriff (PDF)

Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone

Forensic toxicology, 2020, Vol.38 (1), p.59-69

2020

Volltextzugriff (PDF)

Characterization and Metabolism of Drug Products Containing the Cocaine-Like New Psychoactive Substances Indatraline and Troparil

Metabolites, 2024-06, Vol.14 (6), p.342

2024

Volltextzugriff (PDF)

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Cancer research (Chicago, Ill.), 2009-04, Vol.69 (7), p.2996-3003

2009

Volltextzugriff (PDF)

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs

Cancer cell international, 2018-05, Vol.18 (1), p.69-69, Article 69

2018

Volltextzugriff (PDF)

Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver Microsomes

Metabolites, 2020-12, Vol.11 (1), p.3

2020

Volltextzugriff (PDF)

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

Journal of experimental & clinical cancer research, 2014-02, Vol.33 (1), p.15-15, Article 15

2014

Volltextzugriff (PDF)

Targeting adipose tissue

Diabetology and metabolic syndrome, 2012-10, Vol.4 (1), p.43-43, Article 43

2012

Volltextzugriff (PDF)

NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells

The Journal of pharmacology and experimental therapeutics, 2010-01, Vol.332 (1), p.238

2010

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells

The Journal of biological chemistry, 2008-01, Vol.283 (2), p.739-750

2008

Volltextzugriff (PDF)

Y-Box–Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy

Journal of clinical oncology, 2009-12, Vol.27 (36), p.6144-6151

2009

Volltextzugriff (PDF)

Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer

European journal of clinical pharmacology, 2014-07, Vol.70 (7), p.791-798

2014

Volltextzugriff (PDF)

Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist

The Journal of pharmacology and experimental therapeutics, 2002-05, Vol.301 (2), p.720

2002

Volltextzugriff (PDF)

Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist

Naunyn-Schmiedeberg's archives of pharmacology, 2002-12, Vol.366 (6), p.543-550

2002

Volltextzugriff (PDF)

Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro

International journal of pharmaceutics, 2010-04, Vol.389 (1), p.10-17

2010

Volltextzugriff (PDF)

Systemic therapy of Cushing's syndrome

Orphanet journal of rare diseases, 2014-08, Vol.9 (1), p.122-122, Article 122

2014

Volltextzugriff (PDF)

Is sunitinib a Narrow Therapeutic Index Drug? – A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues

Regulatory toxicology and pharmacology, 2016-06, Vol.77, p.25-34

2016

Volltextzugriff (PDF)

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

Blood, 2008-04, Vol.111 (7), p.3714-3722

2008

Volltextzugriff (PDF)

Acquired cisplatin resistance in the head–neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1

International journal of cancer, 2008-11, Vol.123 (9), p.2013-2019

2008

Volltextzugriff (PDF)

Resistenzmechanismen von Tumoren gegen Platinkomplexe: Neue Drug Targets und diagnostische Marker

Jahrbuch der Heinrich-Heine-Universität Düsseldorf 2007/2008, 2021, p.249-262

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective

GaBI Journal, 2014-06, Vol.3 (2), p.79-87

2014

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer CellsS

The Journal of biological chemistry, 2007-10, Vol.283 (2), p.739-750

2007

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaPhysical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(19)
Oncology
(11)
Animals
(9)
Cell Line, Tumor
(9)
Female
(8)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Medicine
(6)
Medicine & Public Health
(6)
Pharmacology & Pharmacy
(6)
Pharmacology. Drug Treatments
(6)
Antineoplastic Agents
(5)
Antineoplastic Agents - Pharmacology
(5)
Review
(5)
Tumors
(5)
Apoptosis
(4)
Cisplatin - Pharmacology
(4)
Drug Resistance, Neoplasm
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Platinum resistance in breast and ovarian cancer cell lines

Key results of a series of surveys among German pharmacies, physicians, patients and stakeholders regarding further triptans as potential OTC products

To switch or not to switch—first Germany-wide study from the perspective of pharmacists in the European environment

Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent

Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone

Characterization and Metabolism of Drug Products Containing the Cocaine-Like New Psychoactive Substances Indatraline and Troparil

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs

Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver Microsomes

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

Targeting adipose tissue

NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells

Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells

Y-Box–Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy

Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer

Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist

Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist

Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro

Systemic therapy of Cushing's syndrome

Is sunitinib a Narrow Therapeutic Index Drug? – A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

Acquired cisplatin resistance in the head–neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1

Resistenzmechanismen von Tumoren gegen Platinkomplexe: Neue Drug Targets und diagnostische Marker

Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective

Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer CellsS

Aktive Filter

Suchergebnisse filtern